A Study to Measure the Effects of Using Tradipitant on Nausea and Vomiting After GLP-1R Agonist Use

A Proof of Concept, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of Tradipitant on Nausea and Vomiting After GLP-1R Agonist Administration in Healthy Overweight Class I or Class II Obese Volunteers

The goal of this study is to measure the effects of using Tradipitant after GLP-1R agonist use on nausea and vomiting in healthy overweight, class I, or class II obese volunteers. The study is placebo-controlled with two treatment arms.

Inclusion Criteria:

• Body Mass Index 25-40 kg/m^2 inclusive
• No serious medical problems or chronic diseases, specifically no type I or type II diabetes

Exclusion Criteria:

• Another disorder that contributes to gastrointestinal symptoms
• History of intolerance and/or hypersensitivity to NK-1 receptor antagonists
• History of intolerance and/or hypersensitivity to GLP-1 receptor agonists
• Exposure to any investigational medication within the past 60 days